Quantum Research Reveals Time May Not Always Move Forward
According to the study published in Scientific Reports, the research focused on understanding how time emerges as a ...
New findings on the power of enzymes could reshape biochemistry
Using a series of more than 1,000 X-ray snapshots of the shapeshifting of enzymes in action, researchers at Stanford ...
studyfinds1d
Time might not have a fixed direction in quantum systems, physicists show
A study reveals that in the microscopic realm of atoms and subatomic particles the equations describing their behavior remain ...
Simulations reveal Anderson transition for light in 3D disordered systems
The Anderson transition is a phase transition that occurs in disordered systems, which entails a shift from a diffusive state ...
unite14d
10 Best AI Translation Software & Tools (February 2025)
The software offers its text and speech translation via the cloud, and it supports more than 100 languages and 12 speech translation systems that make up the Microsoft Translator ... ensuring that ...
ENDPOINTS NEWS15d
Af­ter more de­lib­er­a­tion, Eng­land agrees to pay for Ver­tex’s gene ther­a­py for sick­le cell dis­ease
Ver­tex Phar­ma­ceu­ti­cals and the Na­tion­al Health Ser­vice in Eng­land have reached a pay­ment deal mak­ing the gene-edit­ed ther­a­py Cas­gevy avail­able to cer­tain peo­ple ...
Morningstar15d
Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk
when it rose 15.92% --Up 15.27% year-to-date --Down 10.17% from its all-time closing high of $516.74 on Nov. 8, 2024 --Up 9.3% from 52 weeks ago (Feb. 2, 2024), when it closed at $424.68 --Down 10 ...
Business Insider15d
Vertex Pharmaceuticals (VRTX) Initiated with a Buy at Cantor Fitzgerald
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...
Business Insider16d
Vertex Pharmaceuticals up 2% at $448 after FDA Journavx approval
17:55 EST Vertex Pharmaceuticals (VRTX) up 2% at $448 after FDA Journavx approval Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
Morningstar16d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
JOURNAVX is the first and only approved non-opioid oral pain signal ... use across all types of moderate-to-severe acute pain -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced ...
The Motley Fool20d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by ... patents locked up into the 2030s and rivals nowhere in sight, Vertex's CF fortress ...
Yahoo Finance22d
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Vertex Pharmaceuticals stock declined almost ... for painful lumbosacral radiculopathy (LSR), a form of peripheral neuropathic pain, which showed largely undifferentiated pain reduction from ...